Emcure Pharmaceuticals Limited has announced a major strategic restructuring of its biopharmaceutical business by acquiring the remaining 12.05% minority stake in Gennova Biopharmaceuticals Limited, making it a wholly owned subsidiary. The company also announced a leadership transition, appointing Samit Mehta to lead Gennova as it sharpens its focus on biologics, biosimilars, and next-generation therapeutic platforms.
The minority stake was previously held by Dr. Sanjay Singh and other shareholders, and its acquisition completes Emcure's ownership of Gennova. According to the company, the move is aimed at simplifying the ownership structure and aligning Gennova more closely with Emcure's long-term growth strategy in biologics and biosimilars. Going forward, Gennova will concentrate on expanding its biologics portfolio, including Elaxim®/TENECTASE®, Vintor®, Xgrast®/PEGEX®, and Hamsyl®, while accelerating biosimilar development using its established mammalian and microbial biomanufacturing platforms.
Announcing the development, Satish Mehta, Managing Director and CEO of Emcure Pharmaceuticals, acknowledged Dr. Sanjay Singh's nearly two decades of scientific leadership, crediting him with building Gennova's research capabilities, product portfolio, and innovation-driven culture. He said that the complete acquisition strengthens Emcure's strategic direction and positions Gennova for its next phase of growth under Samit Mehta's leadership.
Commenting on his new role, Samit Mehta, Whole-Time Director and CEO of Gennova Biopharmaceuticals, said the company will continue to serve as Emcure's dedicated biologics and biosimilars platform under the "One Emcure" framework. He added that Gennova will work in close alignment with Emcure's broader research and development priorities while maintaining a strong focus on quality, execution, and disciplined product development.
Emcure clarified that the transaction is not expected to have any material impact on its consolidated financial performance or capital allocation plans. The company stated that its deleveraging strategy, capital expenditure roadmap, and R&D investment plans will remain unchanged, underscoring that the move is primarily a strategic consolidation to strengthen its position in the rapidly growing biologics and biosimilars segment.
